methyl 2-(2-((tert-butoxycarbonyl)amino)phenyl)-3-cyclohexyl-1-(3-methoxy-3-oxoprop-1-en-2-yl)-1H-indole-6-carboxylate | 1132679-18-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 2-(2-((tert-butoxycarbonyl)amino)phenyl)-3-cyclohexyl-1-(3-methoxy-3-oxoprop-1-en-2-yl)-1H-indole-6-carboxylate
• CAS: 1132679-18-5
• 化学式: C₃₁H₃₆N₂O₆
• 分子量: 532.637
• InChiKey: IQBOAZKNXYJYIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.13
• 重原子数：
  39.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  95.86
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  methyl 2-(2-((tert-butoxycarbonyl)amino)phenyl)-3-cyclohexyl-1-(3-methoxy-3-oxoprop-1-en-2-yl)-1H-indole-6-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 methyl 2-(2-aminophenyl)-3-cyclohexyl-1-(3-methoxy-3-oxoprop-1-en-2-yl)-1H-indole-6-carboxylate
  参考文献：
  名称：

  Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase

  摘要：

  We report the evolutionary path from an open-chain series to conformationally constrained tetracyclic indole inhibitors of HCV NS5B-polymerase, where the C2 aromatic is tethered to the indole nitrogen. SAR studies led to the discovery of zwitterionic compounds endowed with good intrinsic enzyme affinity and cell-based potency, as well as superior DMPK profiles to their acyclic counterparts, and ultimately to the identification of a pre-clinical candidate with an excellent predicted human pharmacokinetic profile. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.068
• 作为产物：
  描述：

  methyl 2-(2-{[(tert-butoxycarbonyl)amino]phenyl})-3-cyclohexyl-1H-indole-6-carboxylate 、 丙炔酸甲酯 在 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 以80%的产率得到methyl 2-(2-((tert-butoxycarbonyl)amino)phenyl)-3-cyclohexyl-1-(3-methoxy-3-oxoprop-1-en-2-yl)-1H-indole-6-carboxylate
  参考文献：
  名称：

  Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase

  摘要：

  We report the evolutionary path from an open-chain series to conformationally constrained tetracyclic indole inhibitors of HCV NS5B-polymerase, where the C2 aromatic is tethered to the indole nitrogen. SAR studies led to the discovery of zwitterionic compounds endowed with good intrinsic enzyme affinity and cell-based potency, as well as superior DMPK profiles to their acyclic counterparts, and ultimately to the identification of a pre-clinical candidate with an excellent predicted human pharmacokinetic profile. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.12.068